Evaluation of Briquilimab's Safety and Efficacy in a Double-Blind, Placebo-Controlled Study for Patients with Allergic Asthma

The primary objective of this study is to evaluate the **safety** and **efficacy** of briquilimab in participants with **allergic asthma**. Allergic asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness and reversible airflow obstruction, often triggered by allergens. Assessing the safety and efficacy of briquilimab is clinically relevant as it may offer a new therapeutic option for managing symptoms and improving the quality of life in individuals affected by this condition.

The clinical trial involves a total of **22 participants** diagnosed with **allergic asthma**. The study population includes both male and female subjects, with an age range encompassing children and adolescents. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data from a diverse group, ensuring representation across different age groups and genders.

The clinical trial is designed as a **double-blind**, placebo-controlled, parallel-group study to assess the safety and efficacy of briquilimab in participants with **allergic asthma**. This trial is categorized as a Phase 3 study, indicating it is in the advanced stages of clinical research. The trial is expected to commence recruitment on September 30, 2024, and is projected to conclude by June 30, 2025. The study will involve a series of visits, beginning with an inclusion visit, where participants will be screened for eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study.

Following the inclusion visit, participants will undergo a series of follow-up visits at regular intervals. These visits are designed to monitor the participants' health, assess the efficacy of the treatment, and ensure the safety of the participants throughout the trial. The follow-up visits will include various assessments and data collection to evaluate the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement in the trial, during which final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as adverse reactions to the treatment, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design ensures that all procedures are conducted in a manner that prioritizes participant safety and the integrity of the collected data.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. Therefore, no further details can be offered in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 30, 2024, with an estimated completion date of June 30, 2025. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the therapeutic benefits of the investigational product. The trial's design will ensure that efficacy is measured accurately and consistently throughout the study duration.